Making a Difference in Patients’ Lives

Myriad Genetics is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties.

Myriad answers the most pressing questions for patients and their healthcare providers. Because we believe every patient should be able to know their risk, their path, their plan and their choices regarding disease.

The question asked by healthcare providers:

What is My Patient’s Risk?

Predictive Medicine

myrisk

Myriad’s product that brings the answers:

Myriad myRisk®

A test that provides accurate knowledge of cancer risk and clear direction for patient care.

Hereditary Cancer Panel

Myriad myRisk® Hereditary Cancer is a scientific advancement revolutionizing hereditary cancer testing. Blending both genetic test status AND personal cancer family history, Myriad myRisk hereditary cancer panel represents the next generation of hereditary cancer risk testing. Myriad myRisk identifies elevated risk for 8 important cancers by analyzing multiple, clinically significant genes. Additionally, Myriad myRisk provides a summary of available medical society guidelines to help you optimize your patients’ medical management. Be confident you know your patients’ cancer risks and appropriate follow-up management with Myriad myRisk Hereditary Cancer.

Myriad’s Custom Hereditary Cancer Quiz

This brief online quiz will help your patients determine whether they should be further evaluated for either Hereditary Breast and Ovarian Cancer syndrome or Lynch syndrome. On average, the quiz takes less than 1 minute to complete.

The question asked by healthcare providers:

What is the Best Treatment Option?

Predictive Medicine

BRACAnalysis CDx

Myriad’s product that brings the answers:

Myriad BRACAnalysis CDx®

A companion diagnostic indended to be used as an aid in treatment decisions making for olaparib, a PARP inhibitor

BRACAnalysis CDx®

(FDA-approved germline BRCA1/2 test) is the only companion diagnostic test intended to be used as an aid in treatment decision making for the PARP inhibitor Lynparza™ (olaparib)

ResultsNow™
Access Myriad Test Results Online

Myriad ResultsNow™ electronically delivers Myriad test results. Easily view your patient’s test results from anywhere there is an internet connection. View from your office, home, on any hand-held device.

The question asked by healthcare providers:

Is My Patient’s Prostate Cancer Aggressive?

Predictive Medicine

Prolaris

Myriad’s product that brings the answers:

prolaris

The first prognostic test that offers a look inside the molecular biology of prostate cancer.

Prolaris®

Prolaris was developed to better measure disease aggressiveness by measuring the expression level of genes involved with cell proliferation. Prolaris adds critical information about prostate cancer, and, in conjunction with clinical parameters such as Gleason score and PSA, helps the physician and patient make personalized treatment decisions for prostate cancer.

Myriad’s Custom Family History Tool

The easy to use, online family history tool can help you identify appropriate patients for hereditary cancer testing before your patients’ scheduled appointment. This quiz can help you pre-qualify patients for testing!

The question asked by healthcare providers:

Is this Melanoma?

Diagnostic Medicine

Is My Patient At Risk?

Myriad’s product that brings the answers:

myriad-mypath

Enhancing diagnosis by determining the likelihood of disease presence.

Myriad myPath® Melanoma

Myriad myPath Melanoma is a unique, clinically validated, molecular test using qRT-PCR methodology to provide valuable, additive diagnostic information unavailable from any other test. At Myriad, we’ve seen the power of genetic insight to expose cancer risk and change lives. We set out to answer the need for a great certainty in diagnosing melanoma by developing a 23-gene expression signature that objectively differentiates malignant melanoma from benign nevi with a high degree of accuracy. When used in conjunction with the clinical and pathologic work-up, the result is a diagnostic test that increases confidence rather than relying on subjective analysis or poorly validated protocols in these difficult cases.

Myriad Publications

Keep up-to-date with current hereditary cancer publications, in peer-reviewed scientific journals, and poster presentations with Myriad authorship.

The question asked by healthcare providers:

How Aggressive is My Patient’s Lung Cancer?

Prognostic Medicine

Myriad’s product that brings the answers:

myriad-myplan

Empowering decision-making by assessing the risk of disease progression, recurrence and mortality.

Myriad myPlan® Lung Cancer

Myriad myPlan® Lung Cancer is an RNA expression signature based on 31 cell cycle progression (CCP) genes – the genes that regulate cell division. Early-stage lung adenocarcinoma tumors with a higher myPlan® Lung Cancer Prognostic Score are predicted to be more aggressive and are associated with a higher lung cancer mortality rate than tumors with a lower score. Knowing the aggressiveness of your patients’ cancer is critical when weighing the factors involved in making treatment decisions.

Myriad Promise™ – Helping Healthcare
Professionals Deliver the Best Medical Care

Myriad believes that every patient should have access to the highest quality genetic testing. That’s why Myriad’s hereditary cancer tests are covered by 97 percent of private insurance companies, 80 percent of patients tested pay nothing out of pocket and the average out of pocket cost is less than $100.

The question asked by healthcare providers:

How Can I Mitigate the Risk?

Predictive Medicine

Myriad’s product that brings the answers:

myriad-colaris

A test for Lynch syndrome & Polyposis syndromes (FAP, AFAP, MAP)

Hereditary Colon Cancer

COLARIS® and COLARIS AP® assess the risk of developing hereditary colorectal cancer by detecting disease-causing mutations in the MLH1, MSH2, MSH6, PMS2, EPCAM, MYH and APC genes, which are responsible for the majority of Lynch syndrome, MYH-associated polyposis (MAP) and adenomatous polyposis syndrome cases. These results help providers and patients make more informed healthcare decisions such as earlier screenings.

Keeping You Informed with the Latest News

The Myriad Pro blog will provide you with all the latest news and updates from the Myriad community. Find the latest infographics, publications, articles and more.

The question asked by healthcare providers:

Is My Patient At Risk?

Predictive Medicine

Myriad’s product that brings the answers:

brac-analysis

A test for Hereditary Breast and Ovarian Cancer (HBOC) syndrome

Hereditary Breast & Ovarian Cancer

BRACAnalysis® testing assesses a woman’s risk of developing hereditary breast or ovarian cancer based on the detection of mutations in the BRCA1 or BRCA2 genes. Approximately 7% of breast cancer and 11 – 15% of ovarian cancer cases are caused by BRCA1 or BRCA2, which are inherited in an autosomal dominant pattern. When assessing hereditary cancer risk, a patient’s personal and family history is collected to investigate the risk for HBOC. Once a patient is identified as being at increased risk of HBOC, genetic test results provide the most accurate means of cancer risk assessment for a patient.

Order a Test Kit

Order a Myriad Test Kit Today!